Alogliptin is an orally administered anti-diabetic drug in the dpp-4 inhibitor class. like other medications for the treatment of type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.